Quanterix’s Post

How are blood-based biomarkers (BBMs) making an impact on Alzheimer’s disease detection? Eisai’s Kathryn Kern Jamison, PhD, and Daryl Rhys Jones, PhD, joined Associate Professor of Neurology at Washington University in St. Louis Suzanne Schindler, MD, PhD, to co-author a Nature Magazine Milestones feature on the importance of accurate, early diagnosis in the era of anti-amyloid therapies. Read it here: https://lnkd.in/gGrxWsfT #AlzheimersDisease #neurology

Alzheimer’s research has moved forward in the recent years with 2 drugs (not considering Biogen’s Aduhelm) currently in market- Eisai’s Leqembi (lecanemab) and the other being Eli Liley’s Donanemab (Kinsula). Previously, the disease could only be confirmed in postmortem brains by the presence of amyloid plaques and tau neurofibrillary tangles, making it difficult for a confirmed diagnosis since cognitive impairment can have many causes. Now, amyloid deposition, toxic tau and neurodegeneration can be detected by imaging and/or fluid biomarkers. Among the different methods of detection, the blood based method is more acceptable to patients, does not require any specialized equipment or training, and is lower in cost compared to amyloid or tau PET scan and CSF testing of biomarkers through lumbar puncture. FDA’s approval of blood based biomarkers in Alzheimer’s disease diagnosis holds promise not only in early disease diagnosis but treatment too.

ATTENTION HEALTHCARE PROVIDERS: Dr. Frederick R. Carrick, Professor of Neurology at the University of Central Florida - College of Medicine, will present at the Handelshøyskolen BI in Olso, Norway, on June 1, 2024. The presentation, entitled “Discussion of Recent Published Research on Wound Healing and Parkinson’s Disease,” will discuss ongoing research into therapies, such as those developed by Gladiator Therapeutics, for neurodegenerative disorders and present investigations and human trials. This will be an exciting and current interactive presentation with time reserved for questions and answers. Learn more here. https://ow.ly/IJcI50RpFYJ #GladiatorTherapeutics #DrFrederickCarrick #UniversityOfCentralFlorida #Neurology #BISchoolOfBusiness #Norway #EmergingTherapies #FarInfrared #StemCell #WoundHealing #ParkinsonsDisease #Parkinsons

Simoa® Neurology 4-Plex D (N4PD) Advantage PLUS Assay is empowering breakthroughs in neurology research 🧠 The N4PD assay enables simultaneous measurement of NfL, GFAP, UCH-L1, and brain-derived Tau (BD-Tau) in both blood and cerebrospinal fluid (CSF). These four biomarkers are crucial in understanding a wide range of neurodegenerative conditions and brain injuries.  Whether research focuses on a single neurology biomarker or explores the complex interactions of multiple markers, the Simoa® N4PD Advantage PLUS assay offers unmatched sensitivity, efficiency, and automated precision. Explore our flyer to uncover how the Simoa® N4PD Advantage PLUS is propelling research. https://bit.ly/3WMwwbk #Neurology #Biomarkers #Neurodegeneration #BDTau

developing new products and solutions is what scientists expect from a leading company and at #Quanterix this is our daily goal and our mindset for the future… stay tuned….mich more is yet to come… #SIMOA #biomarkers #neurology #oncology #development #research #IVD #diagnosticskit #neurodisease #improvment #alzheimerdisease #parkinsondisease #kits #earlydetection #diagnosis #clinicaldiagnosis #neurodegeneration #mentalhealth #mentaldisorder

Great timing for a a deeper dive into the role of precision medicine in neurological disease. The FDA has recently released a guidance document about diagnostic criteria, clinical staging and the selection of appropriate outcome measures, for the early stages of Alzheimer’s Disease. To discover more how biomarker testing is shaping the neurology space read the blow here below! #precisionmedicine #biomarkers

🧬 Participating in clinical research here isn't just about advancing science- it's about offering hope and empowerment to patients facing challenging medical conditions. In the field of neurology, every study we conduct is a step closer to breakthrough treatments and improved quality of life.  MSB Clinical Research Center is currently conducting two clinical trials with novel immunotherapeutics for the treatment of myasthenia gravis, with leading enrollment numbers globally. #neurology #clinicalresearch #MSBCRC #MyastheniaGravis #immunotherapeutics

Great article on the advancements of #precisionmedicine outside of oncology!

We’re attending the European Academy of Neurology (EAN) Congress 2024 in Helsinki, Finland, from June 29th until July 2nd.   Our commitment to advancing neurological research and patient care continues as we present our latest innovations and findings.   This year, we will highlight our work in Friedreich ataxia and Alzheimer's disease, as well as our increased dedication to rare diseases. Learn more: https://ow.ly/TbtX50Spw1i   #EAN2024 | #Biogen | #Neurology | #Innovation | #Healthcare | #HCPs

Excited to share the presentation of my research findings in multiple sclerosis (MS) related to choroid plexus volume at the American Academy of Neurology (AAN) 2024 conference in Denver, CO. My two other posters (not displayed in this post), "The Effects of Smoking on Retinal Layer Thickness in Relapsing Remitting Multiple Sclerosis Patients Using Optical Coherence Tomography" and "The Relationship Between Clinical Hand Dexterity and Diffusion Tensor Imaging Metrics in White Matter tracts of Patients with Multiple Sclerosis" were also presented at this conference. I'm glad to see the impactful translation of our MRI and OCT clinical trials conducted at the MS Center at Wayne State University in the Department of Neurology! These trials represent a significant step forward in our efforts to advance MS research and improve patient care. Recent research suggests that changes in choroid plexus volume may be associated with MS pathology. Alterations in the volume of the choroid plexus could potentially impact the production and circulation of CSF, which in turn may influence the immune response and inflammation characteristic of MS. Understanding these volume disparities in the choroid plexus between different racial cohorts could offer valuable insights into the mechanisms underlying MS progression and its potential disparities among diverse populations. #AAN #neurology #multiplesclerosis